Vorapaxar is a recently approved protease activated receptor - 1 (PAR-1) inhibitor. Platelet
inhibition may also exert positive results on coagulation activation and may beneficially
influence the inflammatory response. Since vorapaxar is the first available substance of a
new class of platelet inhibitors its effects on the human coagulation system and the
inflammatory response will be assessed in the well-established human endotoxemia model.